JP2014516924A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516924A5
JP2014516924A5 JP2014504013A JP2014504013A JP2014516924A5 JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5 JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
less
citrate
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032462 external-priority patent/WO2012138958A1/en
Publication of JP2014516924A publication Critical patent/JP2014516924A/ja
Publication of JP2014516924A5 publication Critical patent/JP2014516924A5/ja
Pending legal-status Critical Current

Links

JP2014504013A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014516924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473121P 2011-04-07 2011-04-07
US61/473,121 2011-04-07
PCT/US2012/032462 WO2012138958A1 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014516924A JP2014516924A (ja) 2014-07-17
JP2014516924A5 true JP2014516924A5 (enExample) 2016-01-28

Family

ID=46969561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504013A Pending JP2014516924A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140023655A1 (enExample)
EP (2) EP3058952A1 (enExample)
JP (1) JP2014516924A (enExample)
KR (1) KR20140018966A (enExample)
CN (1) CN103596585A (enExample)
AU (2) AU2012240050B2 (enExample)
BR (1) BR112013025866A2 (enExample)
CA (1) CA2832556A1 (enExample)
EA (1) EA201391488A1 (enExample)
IL (1) IL228591A0 (enExample)
SG (1) SG193963A1 (enExample)
WO (1) WO2012138958A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2523688T3 (enExample) * 2010-01-15 2018-03-10
EP3578203A1 (en) 2011-10-28 2019-12-11 Integritybio Inc. Protein formulations containing amino acids
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
WO2014169153A1 (en) * 2013-04-10 2014-10-16 Echogen, Inc. Peptide complexes and therapeutic uses
JP6179939B2 (ja) * 2013-07-09 2017-08-16 国立大学法人 筑波大学 高濃度γグロブリン製剤の粘度低下方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20180264081A1 (en) * 2015-01-18 2018-09-20 Gloriana Therapeutics Sarl Therapeutic protein formulations
CN116327921A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3134401A1 (en) 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
BR112022026670A2 (pt) * 2020-07-13 2023-01-24 Merck Patent Gmbh Excipientes de redução da viscosidade e combinações dos mesmos para formulações de proteína altamente concentradas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
JP5133494B2 (ja) 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
SI1556477T1 (sl) * 2002-11-01 2017-12-29 Glaxosmithkline Biologicals S.A. Sušilni postopek
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
CA2701032C (en) * 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
AR069495A1 (es) * 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
NO2523688T3 (enExample) * 2010-01-15 2018-03-10
PL2531218T3 (pl) * 2010-02-04 2019-05-31 Csl Behring Ag Preparat immunoglobuliny
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物

Similar Documents

Publication Publication Date Title
JP2014516924A5 (enExample)
JP2014510152A5 (enExample)
KR102462041B1 (ko) 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
JP2022087255A (ja) キャリア結合剤組成物およびそれを作製および使用する方法
JP2021059593A (ja) 担体および抗体からなる組成物およびその製造および使用方法
JP2019503349A5 (enExample)
CN114616249A (zh) 含有抗pd-l1抗体的稳定制剂
CN108883178A (zh) 含抗体制剂
RU2013155695A (ru) Препараты антител против с-мет
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
JP2018521135A5 (enExample)
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
JP2014522843A5 (enExample)
NZ630020A (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
JP2020537520A5 (enExample)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
US20230203152A1 (en) Engineered anti-il-2 antibodies
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
JP2013543505A5 (enExample)
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения